Skip to Content

BioLine Rx Ltd ADR BLRX

Morningstar Rating
$0.77 +0.01 (1.37%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

BLRX is trading at a 234% premium.
Price
$0.76
Fair Value
$3.54
Uncertainty
Extreme
1-Star Price
$1.78
5-Star Price
$9.43
Economic Moat
Kqyw
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BLRX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$0.76
Day Range
$0.770.79
52-Week Range
$0.512.51
Bid/Ask
$0.77 / $0.78
Market Cap
$61.55 Mil
Volume/Avg
202,211 / 338,588

Key Statistics

Price/Earnings (Normalized)
Price/Sales
4.37
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
79

Comparables

Valuation

Metric
BLRX
BIVI
RYTM
Price/Earnings (Normalized)
Price/Book Value
4.721.4051.38
Price/Sales
4.3733.05
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
BLRX
BIVI
RYTM
Quick Ratio
1.002.433.99
Current Ratio
1.142.454.35
Interest Coverage
−22.85−9.50−17.19
Quick Ratio
BLRX
BIVI
RYTM

Profitability

Metric
BLRX
BIVI
RYTM
Return on Assets (Normalized)
−61.42%−115.58%−77.30%
Return on Equity (Normalized)
−196.43%−256.00%−148.97%
Return on Invested Capital (Normalized)
−111.72%−130.07%−146.66%
Return on Assets
BLRX
BIVI
RYTM
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
DmtclwkcVbyzx$632.3 Bil
Vertex Pharmaceuticals Inc
VRTX
CgwkjrycNbhmwp$126.7 Bil
Regeneron Pharmaceuticals Inc
REGN
SpgvjdbrKplwv$119.2 Bil
Moderna Inc
MRNA
YnzkmdbzRljq$46.6 Bil
Alnylam Pharmaceuticals Inc
ALNY
FdbltlkhzMsbvj$32.4 Bil
argenx SE ADR
ARGX
SghddmqSxch$27.6 Bil
BioNTech SE ADR
BNTX
LvnccxfSmzgj$20.3 Bil
Biomarin Pharmaceutical Inc
BMRN
FnjftzrjNwkzgv$16.1 Bil
United Therapeutics Corp
UTHR
BfhgmthhLntsh$14.5 Bil
Incyte Corp
INCY
PqsgwxhhPhcsjt$12.7 Bil

Sponsor Center